Navigation Links
Clarient to Commercialize Novel Breast Cancer Profile
Date:1/9/2008

Factors that might cause such a difference include, but are not limited to: Clarient's ability to effectively market the Clarient Insight Dx Breast Cancer Profile and market acceptance of the new test, the ability of Prediction Sciences and Clarient to obtain and maintain necessary regulatory approvals to commercialize the Clarient Insight Dx Breast Cancer Profile (including FDA clearance if determined by the FDA to be necessary or if, as expected, the FDA adopts current proposed guidance to regulate certain in vitro diagnostic devices such as the Clarient Insight Dx Breast Cancer Profile), Clarient's ability to continue to develop and expand its diagnostic services business, Clarient's ability to expand and maintain a successful sales and marketing organization, Clarient's ability to maintain compliance with financial and other covenants under its credit facilities, the continuation of favorable third party payer reimbursement for laboratory tests, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying and developing new diagnostic tests or novel markers, Clarient's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.

The company does not assume any obligation to update any forward-looking statements or other information contained in this document.

Contact:

Matt Clawson

Allen & Caron, Inc.

(949) 474-4300

matt@allencaron.com


'/>"/>
SOURCE Clarient
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
3. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
4. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
5. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
6. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
7. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
8. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
9. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
10. First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
11. DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Follow us on LinkedIn ... the world has attracted diverse players including academic ... The early years of nanotechnology development was dominated ... the high risks involved, which deterred private and ... evolving technology have been growing over the years, ...
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 ... engaged in the development of high-value and difficult to ... will be presenting at the 21 st Annual ... New York . Bertrand Liang , chief ... the company,s development programs and business strategy on Friday, ...
(Date:9/19/2014)... -- Dublin ... the addition of the  "Micro Market Monitor : ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The ... segments in the chromatography market. The market was ... to reach $2.0 billion by 2019, at a ...
(Date:9/18/2014)... HealthTronics, Inc ., a ... products and services, announced that a poster related ... versus external beam radiotherapy (EBRT) is being presented ... Association (MAAUA) Annual Meeting in Baltimore, Maryland September ... Cryosurgery and External Beam Radiation as Treatments for ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it has filed a shelf registration statement on Form ... when declared effective by the SEC, will allow Poniard ... to $60 million aggregate amount of its common stock, ...
... Fate Therapeutics, Inc. announced today ... owned by Children,s Hospital Boston and Massachusetts General Hospital. ... supporting hematopoietic stem cells. These proprietary technologies developed ... Program at Children,s Hospital Boston and a scientific founder ...
... CITY, Shandong, China, May 15 /PRNewswire-Asia-FirstCall/ -- China,Biologic ... or the,Company,), one of the leading plasma-based pharmaceutical ... announced that the Company,s,management will present at the ... in New York, NY on May 18, 2009 ...
Cached Biology Technology:Poniard Pharmaceuticals Files Shelf Registration 2Poniard Pharmaceuticals Files Shelf Registration 3Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 2Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 2China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 4
(Date:9/18/2014)... Colo., USA A new GSA Bulletin ... the lower Rio Puerco and Chaco Wash in northern ... rings from salt cedar and willow, investigators were able ... or greater. They then combined this data with aerial ... the history of these arroyos. , Arroyos are deep, ...
(Date:9/18/2014)... McGill University and the Quebec government have discovered ... Canadian Journal of Fisheries and Aquatic Sciences . ... cleansers, or industrial cleansers, to which they are ... size and buoyancy, they may readily pass through ... contaminant in the world,s oceans, but have only ...
(Date:9/18/2014)... information is stored in DNA, tiny strands of nucleic ... bodies. To express this genetic data, our DNA is ... into proteins that perform tasks in our cells. ... of RNA molecule. Unlike all other known RNAs, this ... circRNA molecules are abundant, little has been known about ...
Breaking Biology News(10 mins):Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... of organic produce increases with consumers, growers need more ... and Gary R. Cline (retired) of the Land Grant ... designed to investigate options for reducing the presence of ... roots, shoots, and flowers, and transmit the bacterial wilt ...
... and the Society for Mycotoxin Research have signed an ... , the official journal of the Society. Aimed ... the journal deals with all topics related to mycotoxins, ... issue will appear in March 2009. High-quality original ...
... a $2.9 million, three-year grant from the Minerals Management ... at Austin marine scientists will assess the biological and ... before the area opens for offshore oil drilling. ... Interior) brings together several highly experienced Arctic scientists from ...
Cached Biology News:Controlling cucumber beetles organically 2Mycotoxin Research joins Springer's life sciences journals program 2Marine scientists to assess environment before offshore drilling begins in US arctic waters 2Marine scientists to assess environment before offshore drilling begins in US arctic waters 3
Request Info...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
Biology Products: